AxoGen, Inc.（AXGN）のニュースとイベントAXGNAxoGen, Inc.

Company Expects 24% Revenue Growth for 2026

The company said, "For 2026, we expect full-year revenue growth to be at least 24%, or revenue of at least $279 million, gross margin to be at least 73%, and positive free cash flow for the full-year."

Axogen Reports Q2 Revenue of $69.73M, Beating Consensus

Reports Q2 revenue $69.73M, consensus $67.1M. "We are pleased with our second-quarter revenue performance and the progress we're making across each of Axogen's strategic plan priorities," said Michael Dale, President and CEO of Axogen, Inc. "Our strong growth across all our target markets, continues to reinforce the relevance of our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our revenue guidance and continue advancing our strategic objectives for 2026."

Trace Biosciences Receives Strategic Investment from Axogen

Trace Biosciences announced it has received a strategic investment from Axogen as its technology continues to advance through clinical development. The investment is part of Trace's Series A financing round with additional investors expected to join.